Advagene Biopharma Co (ROCO:6709) EPS (Basic): NT$-1.14 (TTM As of Dec. 2025)


ROCO:6709 Advagene Biopharma Co Ltd ROCO:6709
34 GF Score
Price NT$24.95
! 2 Warning Signs
View Full Analysis

What is Advagene Biopharma Co EPS (Basic)?

Advagene Biopharma Co ROCO:6709 -1.38% 34 EPS (Basic) is NT$-1.14 as of Dec. 2025. GuruFocus rates ROCO:6709 with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Advagene Biopharma Co's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was NT$-0.59. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1.14.

Advagene Biopharma Co's EPS (Diluted) for the six months ended in Dec. 2025 was NT$-0.59. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1.15.

Advagene Biopharma Co's EPS without NRI for the six months ended in Dec. 2025 was NT$-0.59. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -1.15.

During the past 3 years, the average EPS without NRI Growth Rate was 21.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 8.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 10 years, Advagene Biopharma Co's highest 3-Year average EPS without NRI Growth Rate was 30.60% per year. The lowest was -5.40% per year. And the median was 15.40% per year.

Advagene Biopharma Co  (ROCO:6709) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Advagene Biopharma Co EPS (Basic) Related Terms

Advagene Biopharma Co EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Advagene Biopharma Co's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advagene Biopharma Co EPS (Basic) Chart

Advagene Biopharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.87 -2.39 -1.82 -1.26 -1.14

Advagene Biopharma Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.89 -0.59 -0.68 -0.56 -0.59
ROCO:6709
34GF Score
Advagene Biopharma Co Ltd ROCO:6709
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Advagene Biopharma Co EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Advagene Biopharma Co's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-68.289-0)/59.671
=-1.14

Advagene Biopharma Co's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-35.203-0)/65.700
=-0.54

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-1.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of NT$-1.14 mean?
Advagene Biopharma Co (ROCO:6709) has a EPS (Basic) of NT$-1.14 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Advagene Biopharma Co and its competitors.
Is Advagene Biopharma Co's EPS (Basic) too high?
Advagene Biopharma Co's current EPS (Basic) is NT$-1.14. Overall, Advagene Biopharma Co has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Advagene Biopharma Co's EPS (Basic) compare to VRTX and REGN?
Advagene Biopharma Co's EPS (Basic) of NT$-1.14 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Advagene Biopharma Co and its competitors. Advagene Biopharma Co's current EPS (Basic) is NT$-1.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advagene Biopharma Co stock overvalued right now?
Advagene Biopharma Co (ROCO:6709) has a current EPS (Basic) of NT$-1.14. The current EPS (Basic) is NT$-1.14. Advagene Biopharma Co's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Advagene Biopharma Co (ROCO:6709), the current EPS (Basic) is NT$-1.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advagene Biopharma Co Business Description

Address Sector 1, Neihu Road, 6 Floor, No.308, Neihu District, Taipei, TWN, 114
Advagene Biopharma Co Ltd is a Taiwan based immune-modulatory platform-based biotechnology company. The company has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. Its product development includes nasal spray seasonal flu vaccine, nasal spray COVID-19 vaccine, Immunotherapy for COVID-19, Respiratory Allergy Immunotherapy - Allergic Rhinitis and Asthma ,and other vaccines.
34GF Score

Get the complete analysis for ROCO:6709

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$24.95
Price